抑制PKA可以杀死来自复发性急性淋巴细胞白血病患者的L-阿斯巴拉金酶耐药白血病细胞
Jung Kwon Lee1, Xidi Wang2, Jinghua Wang3
1Department of Cell Biology & Anatomy, Arnie Charbonneau Cancer and Alberta Children's Hospital Research Institutes, University of Calgary, Calgary, AB, Canada.
Cell death discovery
|May 27, 2024
概括
复发的儿科急性淋巴细胞白血病 (aLL) 很难治疗. 用像H89这样的抑制剂准蛋白激酶A (PKA) 可以杀死L-氨酸酶耐药的aLL细胞,为患有复发性疾病的儿童提供了新的希望.
科学领域:
- 儿科瘤学 儿科瘤学
- 癌症生物学 癌症生物学
- 分子治疗学分子治疗学
背景情况:
- 复发的儿科急性淋巴细胞白血病 (aLL) 长期治愈率不佳,代表了显著的未满足的临床需求.
- 片受体mu 1 (OPRM1) 损失被确定为aLL.asparaginase耐药性的生物标志物.
- 减少OPRM1表达与较高的L-阿斯巴拉金酶IC50相关,表明化学抵抗.
研究的目的:
- 为了确定针对L-氨酸酶耐药aLL的向治疗候选人.
- 为了研究OPRM1在L-asparaginase诱导的亡中的作用.
- 探索向蛋白激酶A (PKA) 的治疗潜力,以对抗aLL.
主要方法:
- 在aLL细胞中进行全基因组逆转录病毒RNAi查和淘汰研究.
- 使用了OPRM1表达,OPRM1阻断和复发患者的ALL细胞.
- 评估了涉及OPRM1,cAMP,PKA和caspase激活的亡途径;测试了PKA抑制剂 (H89,14-22胺基).
主要成果:
- 通过一连串的过程,L-asparaginase诱导了OPRM1-表达细胞的亡,包括减少cAMP和抑制PKA.
- 在复发的aLL细胞中OPRM1的淘汰和低OPRM1表达赋予了对L-asparaginase的抗性.
- PKA 抑制剂 H89 和 14-22 胺有效杀死 OPRM1 阻断和低 OPRM1 表达的 ALL 细胞.
结论:
- 抑制PKA是一种可行的策略,以克服由OPRM1损失驱动的ALLL中的L-氨酸酶耐药性.
- H89和14-22胺显示出作为L-氨酸酶耐药儿科aLL的治疗剂的潜力.
- 针对PKA提供了一种新的治疗途径,以改善儿科ALLLL复发的结果.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:19Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K